Navigation Links
PDI, Inc. to Hold Second Quarter 2013 Financial Results Conference Call on Monday, August 5, 2013
Date:7/26/2013

PARSIPPANY, N.J., July 26, 2013 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII) today announced that it will release its second quarter 2013 financial results on Monday, August 5, 2013 after the market close and host a conference call beginning at 4:30 pm Eastern time to discuss the results.Access information:Date:Monday, August 5, 2013Time:4:30 pm Eastern timeDial-in numbers:(866) 644-4654 (U.S. and Canada) or (706) 643-1203 Conference ID number:13699000Live web cast:www.pdi-inc.com, under "Investor Relations"The teleconference replay will be available three hours after completion through August 9, 2013 at (800) 585-8367 (U.S. and Canada) or (404) 537-3406. The replay pass code is 13699000. The archived web cast will be available for one year on the company's web site, www.pdi-inc.com, under "Investor Relations."

About PDI, Inc.
PDI is a leading health care commercialization company providing superior insight-driven, integrated multi-channel message delivery to established and emerging health care companies. The company is dedicated to enhancing engagement with health care practitioners and optimizing commercial investments for its clients by providing strategic flexibility, full product commercialization services, innovative multi-channel promotional solutions, and sales and marketing expertise. For more information, please visit the company's website at http://www.pdi-inc.com.


'/>"/>
SOURCE PDI, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. CVS Caremark Corporation To Hold Second Quarter 2013 Conference Call
2. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
3. Mettler-Toledo International Inc. Reports Second Quarter 2013 Results
4. IRIDEX Announces Second Quarter 2013 Conference Call and Release Date
5. Femtosecond Lasers for Cataract Surgery: Market Shares, Strategies, and Forecasts, Worldwide, Nanotechnology, 2013 to 2018
6. Amgen Announces Webcast of 2013 Second Quarter Financial Results
7. NxStage Reports Record Revenue For The Second Quarter Of Fiscal 2013
8. CryoLife Reports Record Second Quarter Revenues
9. Actavis Announces 42% Increase to $2.01 in Second Quarter 2013 Non-GAAP Earnings Per Share
10. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2013 Financial Results
11. Webcast Alert: Heska Announces Second Quarter 2013 Earnings Conference Call Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... YORK , Feb. 27, 2015 Securities ... the board of Salix Pharmaceuticals, Ltd. (NASDAQ: ... $158.00 per share. Concerned SLXP investors are encouraged to ... The investigation focuses upon the shareholder ... agreement, Salix shareholders would receive only $158.00 per share ...
(Date:2/27/2015)... , Feb. 27, 2015 An aggressive campaign ... cut the rate of infection with a dangerous drug-resistant ... Clostridium difficile, or C.diff, is a bacterium ... inflammation of the colon. A recent article in the ... difficile Infection in the United States ...
(Date:2/27/2015)... , Feb. 27, 2015   Synageva BioPharma ... a biopharmaceutical company developing therapeutic products for rare ... (NORD™), the European Organisation for Rare Diseases™ (EURORDIS™), ... world in observing Rare Disease Day. ... patient organizations, industry, and other participants conduct special ...
Breaking Medicine Technology:Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
... Nov. 22, 2011 Cardica, Inc. (Nasdaq: CRDC ... under its distribution agreement and loan commitment with Century Medical. ... the $4 million loan commitment from Century. Under the terms ... balance of all amounts drawn by Cardica will be due ...
... 2011 Regeneron Pharmaceuticals, Inc. (NASDAQ: ... and Drug Administration (FDA) has accepted for review the ... for Subcutaneous Use for the prevention of gout flares ... Drug User Fee Act (PDUFA), the goal for a ...
Cached Medicine Technology:Cardica Achieves Second Milestone Under Century Distribution Agreement 2Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 2Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 3Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 4Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 5Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 6Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 7Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 8
(Date:3/1/2015)... 01, 2015 “ The Barrel Mill ” ... Report, which takes a look at the latest and coolest ... host of NewsWatch and a technology expert, conducted the review ... flavor to drinks. , According to Home Distillation of Alcohol, ... spirits. Well, there’s a pretty cool product that’ll help anyone ...
(Date:2/28/2015)... March 01, 2015 Heart diseases are ... 10 percent of urban adult population and 5 percent ... heart diseases and 20-30 percent of them require specialized ... ailments and coronary vascular diseases (CVD). , A division ... new market research report titled “Indian Coronary Stent Market ...
(Date:2/28/2015)... February 28, 2015 The Classic ... offering a new special. Throughout all of March ... , This service can help overall ... and pain. Patients may notice certain symptoms that suggest ... These symptoms include: , 1.    Pain, clicking, and popping ...
(Date:2/28/2015)... Carlsbad, CA (PRWEB) February 28, 2015 ... developed a promising new gene therapy procedure for the ... progressive blindness in patients. Authored by Dr. ... Oxford and published in the Lancet Medical Journal on ... suffering from choroideremia, a rare genetic disorder that mostly ...
(Date:2/28/2015)... Beach, CA (PRWEB) February 28, 2015 ... needs of Central Coast area residents, recently announced a ... System. It’s a treatment option for new and ... kick off 2015 with a bright, white smile, Dr. ... discounted price of $299, marked down from the regular ...
Breaking Medicine News(10 mins):Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2
... properties blocked bacteria formation, delayed onset of ... (HealthDay News) -- The use of silver-coated ... among intensive-care patients on ventilators, a U.S. ... lead to longer hospital stays, increased costs, ...
... In fact, new study hints they might be hazardous , , ... whether folic acid and vitamin B supplements help the heart ... any good and might have even caused participants harm. , ... -- no benefit of taking vitamin B supplements to reduce ...
... DIEGO, Aug. 19 NuVasive, Inc. (Nasdaq:,NUVA), a ... disruptive surgical treatments for the spine, announced today,that ... Sofamor Danek,alleging patent infringement involving certain NuVasive products., ... "It is not surprising,that Medtronic would attempt to ...
... India and BALTIMORE, Aug. 19 Lupin Ltd.,announced today ... marketing agreement for the AeroChamber Plus(R) line of products ... Lupin,Pharmaceuticals, Inc., USA, will use its 50 person sales ... is a Valved Holding Chamber (VHC) device that is,used ...
... COO, Former Experian Executive Will Lead Private Access, Mission to ... privacy management and ... clinical trials recruitment tools, ALISO VIEJO, Calif., Aug. ... enable management of detailed,privacy preferences for personal health information, announced ...
... MD, August 18, 2008Young researchers presented innovative, early-stage ... a collaborative project of the AUA Foundation and ... August 7-9, 2008. The AUA Foundation hosted the ... the most cutting-edge research in sexual medicine. ...
Cached Medicine News:Health News:Silver-Coated Ventilator Tubes Cut Risk of Pneumonia 2Health News:Vitamin B, Folate Supplements Won't Help Heart 2Health News:Vitamin B, Folate Supplements Won't Help Heart 3Health News:NuVasive Announces Patent Infringement Complaint Brought by Medtronic Sofamor Danek 2Health News:NuVasive Announces Patent Infringement Complaint Brought by Medtronic Sofamor Danek 3Health News:Lupin Enters into a Marketing Alliance with Forest Laboratories, Inc. for AeroChamber Plus(R) Brand in the US - Extends its Franchise with Pediatricians 2Health News:VirtualHealth Technologies, Inc., Announces Its Associate, Private Access, Appoints Marc Kirshbaum as President & COO 2Health News:VirtualHealth Technologies, Inc., Announces Its Associate, Private Access, Appoints Marc Kirshbaum as President & COO 3Health News:New research on sexual function 2
Quantel Medical introduces the new Aviso A/B, a new generation high definition ultrasound system in a unique laptop or desktop PC workstation....
... is the result of years of research ... innovation and value, continues to bring you ... CT 200 is faster and easier to ... The CT 200 is the latest innovation ...
The Excel Series from DGH-KOI is an excellent choice for the ophthalmic surgeon performing cataract and other general ophthalmic procedures. With a broad range of blade options and our special Excel ...
New! Visually superior, micrometer handle, single foot plate, blade extends to 3.0 mm....
Medicine Products: